MIV Studio
One Innovation. Every Path to Adoption.
The Healthcare Evidence-to-Adoption Venture Platform™
Promising healthcare innovations do not succeed through science, capital or communication alone.
They succeed when the right evidence is generated, the right stakeholders understand the value, clinicians and healthcare organizations can integrate the solution into care, patients can participate meaningfully, and a credible path to access and scale is established.
MIV Studio helps healthcare innovators cross the entire evidence-to-adoption gap.
We determine where an innovation belongs, what evidence its stakeholders require, how that evidence can be funded and generated, and how the solution can reach clinicians, patients, healthcare systems, strategic partners and global markets.
Through Medical Impact Ventures, HealthEOR, Audience Generation, MIV Films, ImpactOS™, Patient Signal™ and affiliated investment capabilities, we bring strategy, evidence, funding, implementation, audience activation, storytelling, measurement and venture support together within one integrated platform.
From innovation to evidence. From evidence to adoption. From adoption to measurable impact.
More Than an Accelerator
Most accelerators help companies prepare to raise capital.
Most consultancies provide recommendations.
Most agencies help companies communicate.
Most research organizations generate evidence.
MIV Studio connects the complete journey.
We help emerging and growth-stage healthcare companies define their strongest clinical and economic value, identify the stakeholders most likely to adopt, develop responsible funding pathways, generate evidence, reach clinicians and patients, integrate into healthcare workflows and measure what changes.
We do not simply advise healthcare companies on how to enter the market.
We help them understand what must be true for healthcare to say yes.
We Understand Both Sides of Every Introduction
Relationships can create access.
Understanding creates action.
MIV does not simply introduce innovators to pharmaceutical executives, physicians, academic leaders, healthcare systems, associations or investors. We understand what each stakeholder needs to evaluate, support, implement, fund or adopt an innovation.
Pharmaceutical and Biotechnology Organizations: Medical-affairs priorities, independent medical education, evidence gaps, HEOR, patient engagement, access, implementation and lifecycle strategy.
Medical-Device, Diagnostic and Digital-Health Companies: Clinical validation, professional education, workflow integration, safety, patient selection, adoption, outcomes and real-world use.
Academic Medical Centers: Scientific partnerships, investigators, study development, publications, institutional processes, research credibility and dissemination.
Community and Rural Care: Operational barriers, referral leakage, staffing and capacity constraints, access challenges and the realities of implementing innovation outside major academic centers.
Associations, Foundations and Advocacy Organizations: Member education, professional engagement, advocacy, registries, global initiatives, donor evidence, patient support and scientific dissemination.
Clinicians and Care Teams: Clinical relevance, scientific credibility, workflow burden, peer education, decision support and the practical requirements of changing care.
Patients and Caregivers: Care-seeking behavior, trust, communication, shared decision-making, access friction, expectations, persistence and the lived experience of navigating healthcare.
Investors and Strategic Buyers: Evidence risk, adoption risk, clinical workflow, market pathways, value-creation milestones, scalability and strategic exit potential.
The MIV advantage is not only knowing the right people. It is understanding what will cause the right people to act.
The MIV Evidence-to-Adoption Closed Loop
1. Position: Define the innovation’s strongest clinical, patient, economic and strategic value proposition.
We clarify the unmet need, priority population, most credible use case, supporting evidence, competitive differentiation and milestones required to create meaningful enterprise value.
2. Route: Identify the most effective pathway to adoption.
The right route may involve pharmaceutical or biotechnology partners, medical-device companies, academic health systems, community or rural networks, professional associations, advocacy organizations, payers, employers, public-health organizations or direct clinician and patient engagement.
3. Fund: Build a responsible financing strategy around the company’s development and evidence needs.
MIV Studio can support non-dilutive funding strategy, grant opportunity assessment, scientific proposal development, strategic partnership planning, investor readiness, academic collaborations and evidence-based milestone planning.
Approved funding remains governed by the applicable scientific, contractual, sponsor and compliance requirements.
4. Prove: Generate the evidence stakeholders need to believe, adopt and invest.
Capabilities may include evidence-gap assessments, HEOR, real-world research, health-economic modeling, patient and clinician intelligence, patient-reported outcomes, clinical pilots, implementation science, quality improvement and publication planning.
5. Reach: Place credible evidence and compelling stories in front of the audiences capable of changing the company’s trajectory.
Through Audience Generation, MIV Films and our professional networks, we activate clinicians, patients, caregivers, organizations and strategic partners through digital engagement, education, research recruitment, expert participation, scientific communication and cinematic storytelling.
Clinical credibility + precision audience reach + scientific storytelling + measurable action.
6. Integrate: Help innovations become part of real clinical conversations, decisions and workflows.
We support patient-identification pathways, diagnostic and testing workflows, referrals, clinical decision support, multidisciplinary coordination, shared decision-making, access navigation, site readiness and community implementation.
7. Measure: Determine what changed, why it changed and what barriers remain.
ImpactOS™ and Patient Signal™ can examine clinical readiness, patient motivation, care-seeking behavior, shared decision-making, access friction, workflow adoption, implementation progress, patient experience, longitudinal outcomes and sustainability.
8. Scale or Invest: Convert evidence and adoption into growth.
MIV may help selected companies expand into new sites or markets, establish strategic partnerships, prepare for additional financing, pursue licensing opportunities, enter co-development arrangements or become part of an MIV-affiliated investment portfolio.
An Integrated Platform Built to Take Innovation the Last Mile
Medical Impact Ventures
Medical affairs, independent education, patient engagement, implementation science, quality improvement, outcomes measurement and evidence dissemination.
HealthEOR: HEOR, real-world evidence, health economics, value strategy, market-access evidence and outcomes research.
Audience Generation: Precision clinician and patient reach, digital engagement, audience development, research recruitment and measurable activation.
MIV Films: Award-winning healthcare storytelling that combines scientific integrity, patient experience and cinematic execution.
ImpactOS™
A developing evidence-adoption intelligence platform designed to connect patient, clinician, system, intervention and outcome signals.
Patient Signal™: Longitudinal patient intelligence examining why people seek care, delay care, make decisions, encounter friction, persist, disengage or experience different outcomes.
MIV Capital, Risk & Disputes Advisory™: Clinical, evidence, adoption and commercial intelligence for investors, boards, strategic buyers, portfolio companies and counsel.
MIV Ventures: Selective venture building, equity participation, co-development and investment in healthcare companies where MIV’s capabilities can materially improve the probability of success.
Patient Signal™
Understanding the Human Journey Traditional Data May Miss
Claims, clinical records and conventional market research reveal important parts of healthcare.
They may not fully explain why a patient first recognized the need for care, what finally caused the patient to act, why treatment was delayed, which information created trust, how decisions were made, where access failed or why the patient persisted or disengaged.
Patient Signal™ is designed to examine those questions longitudinally across therapeutic areas, populations and care settings.
It can help reveal:
-
Why patients seek or postpone care
-
What creates confidence or mistrust
-
How patients and caregivers make decisions
-
Where referral and access pathways break down
-
How expectations compare with actual experience
-
Why patients initiate, persist, switch or discontinue
-
Whether the eventual decision reflected what mattered most to them
When connected with clinician readiness, healthcare-system capacity and implementation activity, Patient Signal can help answer:
What did the patient need, what did the clinician understand, what could the system deliver and what intervention changed the result?
ImpactOS™
A Learning System for Evidence Adoption
Every appropriate MIV engagement can generate insight into why clinicians adopt or resist an innovation, which evidence changes decisions, what prevents workflow integration, where patients encounter friction and which interventions create measurable change.
ImpactOS™ is being developed to connect those signals across projects, therapeutic areas and care settings.
Over time, appropriately governed and contractually permitted information can strengthen MIV’s methods, benchmarks and recommendations.
The objective is to help innovators answer a critical question:
For a company like ours, which evidence, stakeholder pathway and implementation model are most likely to produce responsible adoption?
The Adoption Pathway Blueprint™
A Practical 18-Month Roadmap
The Adoption Pathway Blueprint™ is a structured strategy engagement designed to identify:
-
Priority markets and use cases
-
Clinical and economic positioning
-
Evidence requirements
-
Patient and clinician needs
-
Stakeholder pathways
-
Funding opportunities
-
Medical-affairs priorities
-
HEOR and outcomes needs
-
Workflow and access barriers
-
Education and communication requirements
-
Pilot opportunities
-
Strategic partnerships
-
Milestones for financing, adoption and scale
The result is not another strategy presentation that sits on a shelf.
It is an actionable evidence-to-adoption plan.
MIV Stakeholder Graph™
The Right Stakeholders. The Right Pathway. The Right Moment.
MIV is developing a structured relationship and intelligence framework spanning pharmaceutical and biotechnology companies, medical-device organizations, academic institutions, health systems, community and rural networks, associations, clinicians, investigators, patients, advocacy groups, payers, employers, investors and strategic buyers.
The value is not simply the size of the network.
It is our ability to identify which stakeholders matter, what each requires and how they fit within a coherent adoption strategy.
Who We Partner With
MIV Studio is designed for evidence-ready companies working across:
Therapeutics and biotechnology, medical devices, diagnostics, biomarkers, digital health, healthcare artificial intelligence, clinical-trial technology, patient engagement, oncology, hematology, neurology, migraine, rare disease, women’s health, aesthetics, reconstruction, population health, health-system workflow, real-world evidence and value-based care.
Evidence-Ready Wellness
MIV Studio is selective about wellness.
We prioritize innovations with credible scientific rationale, responsible claims, measurable health or functional outcomes, a defined clinician, health-system, payer or employer use case, appropriate regulatory positioning and a realistic evidence-generation strategy.
This may include selected innovations in longevity, sleep, nutrition, women’s health, aesthetics, recovery, prevention and quality of life.
Ways to Work With MIV Studio
Strategic Services: Defined consulting engagements covering positioning, evidence, HEOR, medical affairs, funding, implementation, audience strategy, storytelling or market entry.
MIV Venture Accelerator: A structured program supporting evidence strategy, stakeholder access, financing readiness, adoption planning and measurable company-development milestones.
Equity-for-Services Partnerships: For carefully selected companies, MIV may accept an appropriately structured portion of compensation in equity, warrants or another negotiated ownership interest.
Co-Development: MIV may collaborate with selected companies to develop evidence programs, data products, educational platforms, patient solutions, workflow tools or market-entry initiatives.
Selective Seed Investment: MIV-affiliated investment vehicles may invest in companies where the innovation is credible, the unmet need is meaningful and the MIV platform can materially improve the probability of success.
Investor and Portfolio Advisory: MIV advises private-equity firms, venture funds, family offices, strategic investors and portfolio-company boards on evidence strength, patient demand, clinical adoption, workflow readiness, access, scalability and post-investment value creation.
For Investors, Funds and Strategic Buyers
See the Healthcare Risk the Financial Model Cannot Show
Healthcare investments frequently depend on questions that financial diligence alone cannot answer.
Will clinicians use the product?
Will patients seek and accept it?
Does it fit into clinical workflow?
Is the evidence sufficient?
Can the company demonstrate clinical and economic value?
What will prevent adoption?
What must happen during the first 100 days after investment?
MIV provides evidence-to-adoption diligence, Patient Signal research, clinical and workflow assessment, strategic market-pathway analysis and portfolio-company value-creation planning.
We help investors understand not only whether an opportunity appears attractive—but what must be true for it to succeed.
Capital, Risk and Disputes Advisory
MIV provides objective healthcare-industry analysis for investors, boards, strategic buyers, portfolio companies and counsel.
Engagements may include:
-
Scientific and evidence diligence
-
Clinical-adoption assessment
-
Patient and caregiver research
-
Workflow and implementation analysis
-
HEOR and value-evidence review
-
Portfolio-company growth planning
-
Industry-practice analysis
-
Non-testifying litigation consulting
-
Expert reports and testimony within areas of demonstrated expertise
MIV’s role is to clarify the complete healthcare picture—from evidence and patient behavior to implementation, adoption, value and risk.
Independent by Design
MIV’s integrated capabilities are governed through clearly defined roles, contracts and firewalls.
MIV Studio provides venture and commercialization strategy.
HealthEOR conducts separately governed evidence and outcomes work.
Audience Generation provides appropriately contracted audience and communication services.
MIV Ventures conducts separately governed investment activity.
Independent educational programs remain needs-driven, scientifically controlled and protected from commercial influence.
Patient and clinician information is handled according to the consent, privacy, contractual, research and data-governance requirements applicable to each engagement.
Integration creates value. Independence, transparency and scientific integrity protect it.
Why MIV Studio
Most organizations see one part of the healthcare journey.
MIV sees the complete system:
Science. Evidence. Funding. Clinicians. Patients. Systems. Access. Storytelling. Adoption. Outcomes. Capital.
We bring together the strategy to identify the right path, the relationships to reach the right stakeholders, the capabilities to execute and the measurement to prove what happened.
We Do Not Merely Help Healthcare Companies Enter the Market.
We Help Them Find the Right Path, Prove the Value, Reach the Right People and Change Care.
